Miracell Selected as National Innovator in the Health and Diagnostics Sector
Miracell Selected as National Representative Innovative Company in Health and Diagnostics [Medical Newspaper/Daily Newspaper=Reporter Kim Won-jun] Stem cell specialist Miracell has been selected as a “National Representative Innovative Company” by the government. Miracell (CEO Shin Hyun-soon) announced on the 1st that it was selected as a National Representative Innovative Company by the Financial Services Commission, based on evaluations by nine government ministries, including the Ministry of Trade, Industry and Energy and the Ministry of Health and Welfare. Miracell was selected as one of the “Health and Diagnostic Innovative Companies” in the health technology, medical device, and innovative pharmaceutical sectors, based on selection criteria established by the Ministry of Health and Welfare. Miracell, a stem cell specialist company launched in 2009 with the introduction of Harvard University’s cell extraction technology, successfully developed a “minimally manipulated stem cell isolation and amplification source technology” in 2017. The Ministry of SMEs and Startups selected this technology as a technology development project for commercialization by small and medium-sized enterprises. In particular, based on this technology, Miracell successfully developed and domestically produced SMART M-CELL2, a replacement for the SmartPReP2 kit developed by the Harvard Medical School Immunology Research Institute in 2018 and exported worldwide. CEO Shin Hyun-soon stated, “Being selected as a national innovative company is very significant. This opens up a new avenue for scientifically treating rare and intractable diseases, including Parkinson’s disease and intractable chronic renal failure, using stem cells.” Meanwhile, Miracell, which began its medical business in 1986, has been dedicated to research and development as a stem cell specialist since 2007. In particular, its biological drug manufacturing technology has been certified by the Ministry of Health and Welfare as a new medical technology for treating conditions such as acute myocardial infarction, critical limb ischemia, and cartilage defects. In addition, the company has secured core technologies through GMP, ISO13485, ISO9001, and CE certifications, as well as 22 patent applications for cell extraction technology. Source: Medical Newspaper (http://www.bosa.co.kr)
Stem cell company Miracell selected as a “National Innovative Company.”
Stem cell company Miracell selected as a “National Innovative Company Representative” ▲ Stem cell company Miracell announced on the 1st that it has been selected as one of the companies in the government’s “1,000 National Innovative Companies Representative” project. This project aims to foster innovative and technologically advanced small and medium-sized enterprises and venture companies, and the government will select a total of 1,000 companies and provide financial support. Miracell is a stem cell-based biologic product research and development (R&D) company. (Seoul = Yonhap News)
Miracell selected as one of the nation’s top 1000 innovative companies in the health and diagnostics sectors.
Miracell selected as one of the nation’s top 1000 innovative companies in the health and diagnostics sectors. Smart Mcell 2 Successfully Localizes Advanced Bone Marrow and Blood Stem Cell SystemsMiracell, a stem cell specialist, has been selected by the government as one of the “National 1000 Innovative Companies.” Miracell (CEO Shin Hyun-soon) announced on the 1st that it was selected for the third round of the “National 1,000 Innovative Companies,” a program announced by the Financial Services Commission based on evaluations by nine government ministries, including the Ministry of Trade, Industry and Energy and the Ministry of Health and Welfare. The “National 1,000 Innovative Companies” program, launched on July 30, 2020, was approved at the 12th meeting of the Central Emergency Economic Response Headquarters. The program, which involved nine ministries, including the Ministry of Trade, Industry and Energy, the Ministry of SMEs and Startups, the Ministry of Science and ICT, the Ministry of Health and Welfare, and the Ministry of Oceans and Fisheries, selects representative innovative companies by industry and provides them with exceptional financial support to foster them as future core companies. ⓒKorea Medical Association NewspaperStarting with 32 companies in the first round, 247 were selected in the second round, and 321 companies were selected this time. The Financial Services Commission plans to select a total of 1,000 representative innovative companies by industry by 2022. Miracell was selected as one of the “Health and Diagnostic Innovation Companies” in the health technology, medical device, and innovative pharmaceutical categories, based on selection criteria established by the Ministry of Health and Welfare. Launched in 2009 with the introduction of Harvard University’s cell extraction technology, Miracell successfully developed a “Minimally Manipulated Stem Cell Isolation and Amplification Source Technology” in 2017, and the Ministry of SMEs and Startups selected this technology for a small and medium-sized enterprise commercialization technology development project. Based on this technology, Miracell successfully domestically developed and produced SMART M-CELL2, a replacement for the SmartPReP2 kit developed by the Harvard Medical School’s Immunology Research Institute in 2018 and exported globally. Test results at Seoul National University Bundang Hospital showed that its performance was comparable to or even superior to that of SMART M-CELL2. SMART M-CELL2 is a device that extracts large quantities of automatically separated stem cells by centrifuging bone marrow blood extracted from the body. It is currently used in major hospitals both domestically and internationally. Recognized as an innovative technology, SmartMcell2 is a cutting-edge system for “bone marrow and blood stem cell manufacturing,” using biological pharmaceutical manufacturing technology to extract hematopoietic stem cells (CD34+) from blood and mesenchymal stem cells from bone marrow. Approximately 2.9 billion cells can be isolated and extracted in less than an hour, with a cell viability rate of 80-98%. Its automated system, which eliminates air contact and prevents cell mutation, is characterized by its closed, air-tight system. Equipped with special LEDs to enhance cell activity, SmartMcell2 has transitioned from analog to digital. It also features voice support, making it a perfect fit for cutting-edge bio-healthcare medical devices. CEO Shin explained, “Stem cell treatment involves extracting bone marrow blood from the patient’s body, concentrating it through centrifugation, extracting a large quantity of stem cells, and then reinjecting them into the body. This process effectively improves bodily functions, as old cells regenerate into healthy ones.” Source: Korean Medical Association Newspaper (http://www.doctorsnews.co.kr)
[Kyunghyang Shinmun] Miracell Selected as Innovative Company in Health and Diagnostics
Miracell Selected as an Innovative Company in the Health and Diagnostics Sector Stem cell specialist Miracell (CEO Shin Hyun-soon) announced on the 1st that it has been selected as one of the government’s “1,000 Innovative Companies.” The “1,000 Innovative Companies” program, organized by nine ministries including the Ministry of Trade, Industry and Energy, the Ministry of SMEs and Startups, the Ministry of Science and ICT, the Ministry of Health and Welfare, and the Ministry of Oceans and Fisheries, selects leading innovative companies by industry.This program aims to foster these companies as future core businesses through innovative financial support. Starting with 32 companies selected in the first round, 247 companies were selected in the second round, and 321 companies were selected in the third round. Miracell Selected as an Innovative Company in the Health and Diagnostics SectorMiracell was selected as one of the “Innovative Companies in the Health and Diagnostics Sector” in the fields of new health technologies, medical devices, and innovative pharmaceuticals, based on selection criteria established by the Ministry of Health and Welfare. This company, a stem cell specialist launched in 2009 by adopting Harvard University’s cell extraction technology,succeeded in developing the “Minimum Manipulation Stem Cell Isolation and Amplification Source Technology” in 2017, and the Ministry of SMEs and Startups selected this technology as a small business commercialization technology development project. Based on this technology, the company independently developed and successfully domestically produced the Smart Mcell 2. The Smart Mcell 2 extracts bone marrow blood, concentrates it through centrifugation, and automatically separates a large quantity of stem cells. It is currently used in major hospitals both domestically and internationally.Its unique feature is its automated, closed system, which prevents air contact and prevents cell deformation. The Smart Mcell 2 is equipped with a special LED to enhance cell activity, converting the existing analog method to digital. It also features voice support,making it a highly regarded, cutting-edge bio-healthcare medical device.
[MBN] Miracell Selected as One of the “Top 1000 Innovative Companies in the Nation”
Miracell selected as one of the “1000 Innovative Companies” Stem cell company Miracell has been selected as one of the government’s “1,000 Leading Innovative Companies.” Miracell (CEO Shin Hyun-soon) announced on the 1st that it was selected for the third round of the “1,000 Leading Innovative Companies” program, announced by the Financial Services Commission, based on evaluations by nine government ministries, including the Ministry of Trade, Industry and Energy and the Ministry of Health and Welfare. The “1,000 Leading Innovative Companies” program, comprised of nine ministries including the Ministry of Trade, Industry and Energy, the Ministry of SMEs and Startups, the Ministry of Science and ICT, the Ministry of Health and Welfare, and the Ministry of Oceans and Fisheries, selects leading innovative companies by industry and provides them with exceptional financial support to foster them as future core companies. Launched on July 30, 2020,the program was approved at the 12th meeting of the Central Economic Response Headquarters. Starting with 32 companies in the first round, 247 were selected in the second round, and 321 companies were selected this time. The Financial Services Commission plans to select 1,000+ representative innovative companies from each industry by 2022. Miracell was selected as one of the “Health and Diagnostic Innovative Companies” in the health technology, medical devices, and innovative pharmaceuticals categories, based on selection criteria established by the Ministry of Health and Welfare. Launched in 2009 with the introduction of Harvard University’s cell extraction technology, Miracell successfully developed a “Minimally Manipulated Stem Cell Isolation and Amplification Source Technology” in 2017. The Ministry of SMEs and Startups selected this technology for a small business commercialization technology development project. Based on this technology, Miracell successfully developed and domestically produced SmartPReP2, a kit developed by the Harvard Medical School’s Immunology Research Institute in 2018 and exported globally, and SMART M-CELL2, a replacement kit. Test results from Seoul National University Bundang Hospital showed that its performance was comparable to or even superior to SmartPReP2. Smart Mcell 2 is a device that extracts large quantities of automatically separated stem cells from bone marrow blood extracted from the body through centrifugation. It is currently used in major hospitals both domestically and internationally. CEO Shin Hyun-soon stated, “Being selected as a National Representative Innovative Company is very significant. It opens up new avenues for scientifically treating rare and intractable diseases, including Parkinson’s disease and intractable chronic renal failure, using stem cells.” CEO Shin continued, “Stem cell therapy involves extracting bone marrow blood from the patient, concentrating it through centrifugation, extracting a large quantity of stem cells, and then reinjecting them into the body. Because old cells regenerate into healthy ones, it is highly effective in improving bodily functions.” Recognized as an innovative technology, Smart Mcell 2 is a cutting-edge system for “bone marrow and blood stem cell manufacturing,” using biological pharmaceutical manufacturing technology to extract hematopoietic stem cells (CD34+) from blood and mesenchymal stem cells from bone marrow. Approximately 2.9 billion cells can be isolated and extracted in one session,within an hour, and cell viability rates reach a remarkable 80-98%.Its automated system features a closed, air-tight system that prevents cell deformation. Smart Mcell 2 is equipped with special LEDs to enhance cell activity, converting the existing analog system to digital, and even features voice support, making it a perfect fit for cutting-edge bio-healthcare medical devices. Meanwhile, Miracell, which began its medical business in 1986, has been dedicated to research and development as a stem cell specialist since 2007. In particular, our biological pharmaceutical manufacturing technology has been certified by the Ministry of Health and Welfare as a new medical technology that helps treat conditions such as acute myocardial infarction, critical limb ischemia, and cartilage defects. We also have secured core technologies through GMP, ISO13485, ISO9001, and CE certifications, and 22 patent applications for cell extraction technology.
[Edaily] Miracell Selected as One of the Top 1000 Innovative Companies in the Health and Diagnostics Sector
Miracell selected as one of the nation’s top 1000 innovative companies in the health and diagnostics sector. ▶ View original article [Edaily Reporter Lee Soon-yong] Stem cell company Miracell has been selected as one of the government’s “1000 Innovative Companies.” Miracell (CEO Shin Hyun-soon) announced on the 1st that it has been selected for the third round of the “1000 Innovative Companies,” a list announced by the Financial Services Commission based on evaluations by nine government ministries, including the Ministry of Trade, Industry and Energy and the Ministry of Health and Welfare. The “1000 Innovative Companies” list is a support system for nine ministries, including the Ministry of Trade, Industry and Energy, the Ministry of SMEs and Startups, the Ministry of Science and ICT, the Ministry of Health and Welfare, and the Ministry of Oceans and Fisheries. It selects leading innovative companies by industry and provides them with exceptional financial support to foster them as future core companies. The program was launched on July 30, 2020, with a resolution passed at the 12th Central Economic Response Headquarters meeting. Starting with 32 companies selected in the first round, 247 were selected in the second round, and 321 companies were selected this time. The Financial Services Commission plans to select a total of 1,000+α representative innovative companies in each industry by 2022. Miracell was selected as one of the “Health and Diagnostic Innovative Companies” in the health technology, medical device, and innovative pharmaceutical sectors, based on selection criteria established by the Ministry of Health and Welfare. Miracell is a stem cell company launched in 2009 with the introduction of cell extraction technology from Harvard University. In 2017, it successfully developed a “minimally manipulated stem cell isolation and amplification source technology,” and the Ministry of SMEs and Startups selected this technology as a technology development project for commercialization by SMEs. In particular, based on this technology, the company successfully developed and domestically produced SMART M-CELL2, a replacement for the SmartPReP2 kit developed by the Harvard Medical School’s Immunology Research Institute in 2018 and exported worldwide. Test results at Seoul National University Bundang Hospital showed that its performance was comparable to or even superior to that of SMART M-CELL2. SMART M-CELL2 is a device that extracts large quantities of automatically separated stem cells by concentrating bone marrow blood extracted from the body through centrifugation. It is currently used in major hospitals both domestically and internationally. CEO Shin Hyun-soon stated, “Being selected as a national innovative company is very significant. It has opened up new avenues for scientifically treating rare and intractable diseases, including Parkinson’s disease and intractable chronic renal failure, using stem cells.” He continued, “Stem cell therapy is a treatment that extracts bone marrow blood from the patient, concentrates it through centrifugation, extracts a large amount of stem cells, and then injects them back into the body.” He explained, “Because old cells are regenerated into healthy ones, the treatment is highly effective in improving the body’s functions.” Smart Mcell 2, recognized as an innovative technology, is a cutting-edge system for “bone marrow and blood stem cell manufacturing,” using biological pharmaceutical manufacturing technology to extract hematopoietic stem cells (CD34+) from blood and mesenchymal stem cells from bone marrow. Approximately 2.9 billion cells can be separated and extracted in less than an hour, with a cell viability rate of 80-98%.Its unique feature is its automated, closed system, which prevents contact with air and prevents cell deformation.Smart Mcell 2 is equipped with special LEDs to enhance cell activity, transitioning from analog to digital. It also features voice support, making it a perfect fit for cutting-edge bio-healthcare medical devices. Meanwhile, Miracell, which began its medical business in 1986, has been dedicated to research and development as a stem cell specialist since 2007. In particular, its biological drug manufacturing technology has been certified by the Ministry of Health and Welfare as a new medical technology that helps treat conditions such as acute myocardial infarction, critical limb ischemia, and cartilage defects. Furthermore, Miracell has secured core technologies through GMP, ISO13485, ISO9001, and CE certifications, as well as 22 patent applications for cell extraction technology.
Miracell Selected as One of the “1000 National Innovative Companies in the Health and Diagnostics Sector”
Miracell Selected as One of the “1000 National Innovative Companies in the Health and Diagnostics Sector” Stem cell specialist Miracell has been selected as one of the government’s “1000 Innovative Companies.” According to the company on the 1st, Miracell was selected for the third round of the “1000 Innovative Companies,” announced by the Financial Services Commission, based on evaluations by nine government ministries, including the Ministry of Trade, Industry and Energy and the Ministry of Health and Welfare. This time, 321 companies were selected. Miracell was selected as one of the “Health and Diagnostic Innovation Companies” in the health technology, medical device, and innovative pharmaceutical categories, according to the Ministry of Health and Welfare’s selection criteria. Launched in 2009 as a stem cell specialist company with the introduction of Harvard University’s cell extraction technology,the company successfully developed a “minimally manipulated stem cell isolation and amplification source technology” in 2017. The Ministry of SMEs and Startups selected this technology as a technology development project for commercialization by small and medium-sized enterprises.In 2018, Miracell successfully developed and domestically produced the Smart Mcell 2 kit, a replacement for the Smart Prep kit developed by the Harvard Medical School’s Immunology Research Institute and exported worldwide. CEO Shin Hyun-soon stated, “Being selected as a national innovative company is very significant. This opens up a new avenue for scientifically treating rare and intractable diseases, including Parkinson’s disease and intractable chronic renal failure, using stem cells.” Meanwhile, Miracell, which began its medical business in 1986, has been dedicated to research and development as a stem cell specialist since 2007. In particular, its biological drug manufacturing technology has been certified by the Ministry of Health and Welfare as a new medical technology that helps treat conditions such as acute myocardial infarction, critical limb ischemia, and cartilage defects. Reporter Kim Si-young kimsy@asiatoday.co.kr
Miracell Selected as One of the “1000 National Innovative Companies in the Health and Diagnostics Sector”
Miracell selected as one of the “1000 National Innovative Companies in the Health and Diagnostics Sector” A stem cell specialist dedicated to research and development Stem cell specialist Miracell has been selected as one of the government’s “1,000 Leading Innovative Companies.” Miracell (CEO Shin Hyun-soon) announced on the 1st that it was selected for the third round of the “1,000 Leading Innovative Companies,” a program announced by the Financial Services Commission based on evaluations by nine government ministries, including the Ministry of Trade, Industry and Energy and the Ministry of Health and Welfare. The “1,000 Leading Innovative Companies” program, launched on July 30, 2020, was approved at the 12th meeting of the Central Disaster and Safety Countermeasures Headquarters. The program selects leading innovative companies by industry and provides them with exceptional financial support to foster them as future core companies. Starting with 32 companies in the first round, 247 were selected in the second round, and 321 companies have been selected this time. The Financial Services Commission plans to select 1,000+ representative innovative companies from each industry by 2022. Miracell was selected as one of the “Health and Diagnostic Innovative Companies” in the health technology, medical device, and innovative pharmaceutical sectors, based on selection criteria established by the Ministry of Health and Welfare. Launched in 2009 with the introduction of Harvard University’s cell extraction technology, Miracell successfully developed a “minimally manipulated stem cell isolation and amplification source technology” in 2017. The Ministry of SMEs and Startups selected this technology for a small business commercialization technology development project. Based on this technology, Miracell successfully localized and independently developed the SMART M-CELL2 kit, a replacement for the SmartPReP2 kit developed by the Harvard Medical School’s Immunology Research Institute in 2018 and exported globally. Test results at Seoul National University Bundang Hospital showed that Miracell’s performance was comparable to or even superior to that of SmartPReP.Smart Mcell 2 is a device that extracts large quantities of automatically separated stem cells from bone marrow blood extracted from the body through centrifugation. It is currently used in major hospitals both domestically and internationally. CEO Shin Hyun-soon (pictured) stated, “Being selected as a National Representative Innovative Company is very significant. It opens up new avenues for scientifically treating rare and intractable diseases, including Parkinson’s disease and intractable chronic renal failure, using stem cells.” He continued, “Stem cell therapy involves extracting bone marrow blood from the patient, concentrating it through centrifugation, extracting a large quantity of stem cells, and then reinjecting them into the body. Because old cells regenerate into healthy ones, it is highly effective in improving bodily functions in the affected area.” Recognized as an innovative technology, Smart Mcell 2 is a cutting-edge system for “bone marrow and blood stem cell manufacturing,” using biological pharmaceutical manufacturing technology to extract hematopoietic stem cells (CD34+) from blood and mesenchymal stem cells from bone marrow. Approximately 2.9 billion cells can be isolated and extracted in less than an hour, with a cell viability rate of 80-98%. Its automated system features a closed, air-tight system that prevents cell deformation. Smart Mcell 2 features a special LED to enhance cell activity, transitioning from analog to digital. It also features voice support, making it a perfect fit for cutting-edge bio-healthcare medical devices. Meanwhile, Miracell, which began its medical business in 1986, has been dedicated to research and development as a stem cell specialist since 2007. In particular, our biological drug manufacturing technology has been certified by the Ministry of Health and Welfare as a new medical technology that helps treat conditions such as acute myocardial infarction, critical limb ischemia, and cartilage defects. Furthermore, we have secured core technologies through GMP, ISO13485, ISO9001, and CE certifications, and 22 patent applications for cell extraction technology.